Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.17.

EBIT: As of FY2026 Q2, the actual value is USD -3.346 M, beating the estimate of USD -3.601 M.

Financial Performance for the Three Months Ended June 30, 2026

• Research and Development (R&D) Expenses: R&D expenses for Azitra, Inc. were $1,351,529 for the quarter ended June 30, 2026, a slight decrease compared to $1,401,839 for the comparable period in 2025.
• General and Administrative (G&A) Expenses: G&A expenses increased to $2,067,639 for the quarter ended June 30, 2026, from $1,469,513 in the comparable period of 2025.
• Total Operating Expenses: Total operating expenses for the quarter were $3,419,168 in 2026, up from $2,871,352 in 2025.
• Loss from Operations: The loss from operations was - $3,419,168 for the three months ended June 30, 2026, compared to - $2,871,352 for the same period in 2025.
• Net Loss: Azitra, Inc. reported a net loss of - $3,347,660 for the quarter ended June 30, 2026, an increase from - $2,888,993 for the comparable period in 2025.
• Net Loss per Share: Basic and diluted net loss per share was - $0.17 for the quarter ended June 30, 2026, compared to - $1.18 for the same period in 2025.

Financial Position as of June 30, 2026

• Cash and Cash Equivalents: As of June 30, 2026, Azitra, Inc. had cash and cash equivalents of $6,727,810, significantly up from $2,068,083 as of December 31, 2025.
• Total Current Assets: Total current assets amounted to $7,443,822 as of June 30, 2026, compared to $3,019,327 as of December 31, 2025.
• Total Assets: Total assets were $8,916,046 as of June 30, 2026, an increase from $5,025,386 as of December 31, 2025.
• Total Current Liabilities: Total current liabilities were $1,530,709 as of June 30, 2026, up from $1,067,966 as of December 31, 2025.
• Total Liabilities: Total liabilities reached $1,581,707 as of June 30, 2026, compared to $1,224,156 as of December 31, 2025.
• Total Stockholders’ Equity: Total stockholders’ equity increased to $7,334,339 as of June 30, 2026, from $3,801,230 as of December 31, 2025.

Operational Metrics and Business Highlights (Q2 2026)

• Azitra, Inc. reported the first preclinical data from ATR-COSF, demonstrating breakthrough repeat-dose distribution, controlled delivery into targeted skin layers, and anti-wrinkle activity in ex vivo human skin.
• The company continued enrollment for the first cohort in the Phase ¹⁄₂ clinical trial evaluating ATR-04 for EGFR inhibitor-associated rash.
• Recombinant protein initiatives, including Tobacco Etch Virus (TEV) Protease and T7 RNA Polymerase, were advanced, expanding the company’s platform into biotechnology research and manufacturing applications.
• Azitra, Inc. issued a CEO Letter to Shareholders detailing an expanded strategy to leverage its microbial genetic engineering platform across therapeutics, cosmetic ingredients, and biotechnology products.
• The company plans to strategically pause further enrollment in the ongoing Phase 1b study evaluating ATR-12 for Netherton syndrome, reflecting a disciplined approach to capital allocation.

Outlook and Upcoming Milestones

Azitra, Inc. plans to advance ATR-COSF toward a planned proof-of-concept clinical study, with a human cosmetic application study expected to start in Q3 2026. The company anticipates reporting topline data from the first cohort of the Phase ¹⁄₂ trial for ATR-04 around year-end 2026. Additionally, Azitra, Inc. will continue developing its recombinant protein portfolio to broaden its long-term commercial potential.